Who Will Reap The BIOSECURE Spoils? U.S. Industry Boost Not Guaranteed

Who Will Reap The BIOSECURE Spoils? U.S. Industry Boost Not Guaranteed

September 18, 2024, Pink Sheet

Steve Rademaker’s commentary was included in a Pink Sheet article examining the BIOSECURE Act and how it will affect U.S. national security and supply chain security. The bill would force the separation of the U.S. pharmaceutical industry from certain Chinese manufacturing and contract development companies. Steve discusses the bill’s likelihood of being passed by the U.S. Congress.

“This bill kind of looked like a juggernaut,” at least until the House floor vote, because it had

cleared the House and Senate committees nearly unanimously, Steve noted. He added that “in truth, it did pass overwhelmingly. It only looks like it didn't do well based on the kind of Washington expectations game. Compared to one no vote in committee, 81 no votes on the House floor sounds like a lot, but still well short of the one-third of the House that would have been necessary to defeat it on the suspension calendar. The bill still has strong bipartisan support, but it doesn’t look to be quite the juggernaut that it did before yesterday.”

The House vote further diminishes the already miniscule chance the bill could have passed the

Senate with a free-standing vote and could embolden some Senators to push back on the bill,

Steve said. “It’s just an unusual posture because until now there hasn’t been sort of an opponent of the bill who would be the natural negotiator with the supporters.”